Kim Giffoni insider trades: Targeted Medical Pharma (TRGM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kim reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 24, 2015 | TRGM | ↓ Sell | 8,580 | $0.01 | $129 | By Trust | Nov 24, 2015 (0d) |
| Nov 24, 2014 | TRGM | ↑ Buy | 700 | $0.50 | $350 | By Trust | Nov 24, 2014 (0d) |
| Apr 9, 2014 | TRGM | ↑ Buy | 5,000 | $0.83 | $4K | Direct | Apr 10, 2014 (1d) |
| Dec 12, 2013 | TRGM | ↑ Buy | 1,000 | $0.90 | $900 | Direct | Dec 16, 2013 (4d) |
| Dec 11, 2013 | TRGM | ↑ Buy | 11,980 | $0.88 | $11K | Direct | Dec 11, 2013 (0d) |
| Dec 2, 2013 | TRGM | ↑ Buy | 4,800 | $1.06 | $5K | Direct | Dec 4, 2013 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Kim Giffoni's insider trades
Kim Giffoni is Chief Executive Officer at Targeted Medical Pharma (TRGM). Since Dec 2, 2013, Kim has reported 5 open-market purchases worth $21K and 1 sale worth $129 on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (3 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TRGM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.